Pfizer vs. Moderna: which biotech stock has better technicals in 2025?

The biotech sector remains a hotbed for investors, with Pfizer (PFE) and Moderna (MRNA) being two of the most discussed stocks. As we move through 2025, both companies face unique challenges and opportunities. This article compares their technical setups to determine which stock presents a better trading opportunity, followed by a list of the top 5 FX and CFD brokers to trade biotech stocks.

 

Pfizer (PFE) technical breakdown

Current price action (2025)

• Last price: ~$23.00
• 52-week range: $20.50 – $28.75
• Market cap: ~$130 billion

Key technical observations

• Trend analysis:
  • The stock has been in a descending channel since peaking in late 2022
  • Recently broke above the short-term downtrend line (bullish signal)
  • 200-day MA at $28 remains a critical resistance
• Support/resistance structure:
  • Immediate support: $22 (psychological + recent lows)
  • Strong support: $20 (multi-year floor)
  • Resistance levels:
    • $25 (recent swing high)
    • $28 (200-day MA + previous support now resistance)

• Momentum indicators:

  • RSI (14): 55 (neutral but improving from oversold conditions)
  • MACD: Bullish crossover recently completed
  • Volume: No significant accumulation yet (needs confirmation)

• Chart patterns:

  • Potential inverse head and shoulders forming (bullish reversal pattern)
  • Neckline at $25 – break above could target $30+

Trading strategy for PFE

• Bullish scenario: Break above $25 with volume → Target $28-30
• Bearish scenario: Failure at $25 → Retest $20 support
• Risk/reward: Favorable above $25, poor below $22

 

Moderna (MRNA) technical breakdown

Current price action (2025)

• Last price: ~$26.00
• 52-week range: $22.00 – $32.50
• Market cap: ~$100 billion

Key technical observations

• Trend analysis:

  • Completed a double bottom at $22 in Q1 2025
  • Currently testing the neckline at $28
  • 50-day MA crossed above 200-day MA (“golden cross”)

• Support/resistance structure:

  • Immediate support: $24 (rising trendline)
  • Strong support: $22 (double bottom low)
  • Resistance levels:
    • $28 (neckline + psychological)
    • $32.50 (2025 high)

• Momentum indicators:

  • RSI (14): 62 (approaching overbought but not extreme)
  • MACD: Strong bullish momentum (histogram expanding)
  • Volume: Increasing on up days (institutional interest)

• Chart patterns:

  • Completed cup and handle pattern in Q2 2025
  • Measured move suggests $36 target if $28 breaks

Trading strategy for MRNA

• Bullish scenario: Break above $28 → Target $32-36
• Bearish scenario: Rejection at $28 → Rangebound $24-28
• Risk/reward: Excellent above $28, manageable below $24

 

Pfizer vs. Moderna comparative analysis: which stock is better?

Short-term traders (1-3 months)

• Moderna offers clearer technical patterns and stronger momentum
• Higher beta (more volatility) provides better swing opportunities
• Clean resistance at $28 makes for easy trade management

Long-term investors (6-12 months)

• Pfizer may offer better value if the reversal confirms
• Higher dividend yield (3.5% vs 0% for MRNA)
• More diversified business reduces single-product risk

Technical edge: Moderna leads

• Stronger momentum indicators across all timeframes
• More institutional volume supporting the move
• Cleaner chart patterns with defined risk levels

 

Top FX and CFD brokers to trade biotech stocks

🎯 Pro tip: Use demo accounts to test trading strategies risk-free before committing capital.

If you’re looking to trade Pfizer, Moderna, or other biotech stocks, here are the best CFD brokers in 2025:

XTB – best for technical traders

• Why choose? Advanced charting tools with 15+ timeframes
• Unique feature: Free access to TradingView charts
• Stock CFD fees: 0.08% commission (competitive)
• Leverage: 1:5 for US stocks

 

eToro – best for Social and Copy trading

• Why choose? CopyPortfolios for biotech sector exposure
• Unique feature: Fractional shares for expensive stocks
• Stock CFD fees: Spread-only pricing
• Leverage: 1:2 for retail clients (protective)

Risk disclaimer: eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 61% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

This communication is intended for information and educational purposes only and should not be considered investment advice or investment recommendation. Past performance is not an indication of future results.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.

 

AvaTrade – best for automated trading

• Why choose? Supports Expert Advisors on MT4/5
• Unique feature: Guaranteed stop losses
• Stock CFD fees: Built into spreads
• Leverage: 1:10 for professional clients

 

BlackBull Markets – best for active traders

• Why choose? True ECN execution (no dealing desk)
• Unique feature: Ultra-fast order execution (<50ms)
• Stock CFD fees: Raw spread + $3 commission
• Leverage: 1:20 for certain instruments

 

Plus500 – best for short-term CFD traders

• Why choose? Simple, intuitive platform
• Unique feature: Free price alerts and notifications
• Stock CFD fees: No commissions (wide spreads)
• Leverage: 1:5 standard

80% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Plus500EE AS is authorised and regulated by the Estonian Financial Supervision and Resolution Authority (Licence No. 4.1-1/18).

 

 

Related articles:

• Stocks trading and investment for beginners: understanding the market and how it works

 

• Forex vs. stock trading: which is better?

 

• How to profit from stock market anomalies: key strategies and best brokers